QPPV.COM KNOWLEDGE ASSESSMENT

Blinatumomab: CD19–CD3 T-cell engagement, acute lymphoblastic leukaemia, and product pharmacovigilance

Test your understanding of the concepts covered by Blinatumomab: CD19–CD3 T-cell engagement, acute lymphoblastic leukaemia, and product pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which data combination would be most useful when evaluating a suspected blinatumomab-related inflammatory event?

Only the patient's treatment indication Cycle and day, tumour burden, dose step, premedication, vital signs, organ involvement and competing infection evidence Only the final outcome after hospital discharge Only the product batch number without clinical chronology

Question 2 of 10 Which finding would most strongly support tumour lysis syndrome rather than isolated CRS in a patient who develops fever after treatment initiation?

A transient headache with normal renal function Hyperkalaemia, hyperphosphataemia, hyperuricaemia and acute kidney injury A positive blood culture with a catheter-site focus A new handwriting abnormality without metabolic changes

Question 3 of 10 Why may blinatumomab be biologically suitable for MRD-positive disease despite its potential for immune-mediated toxicity?

MRD-positive disease has no CD19 expression A lower target burden may reduce explosive immune activation while residual disease remains clinically important MRD-positive disease is always confined to the skin and cannot cause systemic effects Blinatumomab is inactive at low disease burden

Question 4 of 10 Why can flushing the infusion line at the end of a blinatumomab bag create a clinically important medication error?

Flushing chemically inactivates the drug and causes treatment failure The line contains residual drug that may be delivered rapidly as an unintended bolus Flushing prevents any subsequent use of the dedicated lumen The line flush causes CD19 to be expressed on T cells

Question 5 of 10 Which is the most appropriate interpretation of paediatric missing-information categories in the EU RMP?

They prove that blinatumomab causes developmental impairment and secondary malignancy They identify evidence gaps requiring structured long-term observation without asserting causality They apply only to adults treated after HSCT They eliminate the need to monitor children after treatment ends

Question 6 of 10 Which statement about blinatumomab-associated neurological toxicity is most accurate?

It can occur only when CRS is present It is excluded if the patient has no fever or hypotension It may occur with CRS, after CRS, or independently of CRS It is caused by direct binding of blinatumomab to neuronal CD19

Question 7 of 10 Which conclusion is justified by improved survival with blinatumomab added during consolidation in patients who were already MRD-negative?

MRD-negative status proves eradication of every leukaemia cell Blinatumomab has no role after induction A negative MRD assay is a threshold statement and does not prove complete eradication The treatment benefit must result from direct BCR::ABL1 inhibition

Question 8 of 10 A pump malfunction causes an uncertain interruption and possible underdose during home infusion. Which information is most important in the medication-error report?

Only whether the patient reported fever Only the name of the prescribing physician Prescribed dose, concentration, programmed rate, timing, residual volume, alarms and estimated actual exposure Only the patient's diagnosis and age

Question 9 of 10 Why is a baseline neurological examination valuable before starting blinatumomab?

It prevents all subsequent neurological events It provides a comparator for detecting changes in speech, writing, orientation and motor function It confirms that the patient has CD19-positive disease It determines the exact concentration of blinatumomab required

Question 10 of 10 How should a near miss involving incorrect blinatumomab pump programming but no patient exposure generally be handled from a pharmacovigilance perspective?

It has no value because no adverse event occurred It should be documented because it can reveal system weaknesses and support prevention It should be coded as confirmed CRS It should be reported only if the patient later relapses

Blinatumomab: CD19–CD3 T-cell engagement, acute lymphoblastic leukaemia, and product pharmacovigilance

Cookie Settings